⚠ Evidence warning: Clinical trials or other evidence do not support the claim that silicon at typical Western dietary intakes is a major reason historical low-calcium populations kept healthy bones, or that dietary silicon is a proven part of osteoporosis prevention. This page keeps it as a report of what people, websites or other media say.
Silicon for Bone Density
The single most influential observational study of silicon and bone health is Jugdaohsingh, Tucker, Qiao and colleagues' analysis of the Framingham Offspring cohort — 2,847 community-dwelling adults whose dietary silicon intake was estimated from food-frequency questionnaires and whose hip bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry (DXA). Adults in the highest quintile of dietary silicon intake (over 40 mg/day) had hip BMD up to 10% higher than adults in the lowest quintile (under 14 mg/day) — a magnitude comparable to the effect of weight-bearing exercise or vitamin D supplementation. The link was seen in men and premenopausal women but not in postmenopausal women, and a later study in Aberdeen tied that difference to estrogen status. This page walks through the Framingham finding in detail, the silicon-collagen-vitamin-D-K2 axis in bone matrix, the unusually high silicon bioavailability from beer, and what the one supplement trial and the animal studies have and have not shown.
Table of Contents
- The Bone Matrix Two-Phase Architecture
- The Framingham Offspring Silicon-BMD Study
- Estrogen Modulation of the Silicon Effect
- Bioavailability: Beer, Mineral Water, Whole Grains
- The Silicon-Aluminum Interaction
- The Silicon-Vitamin-D-Vitamin-K2 Axis
- Osteoblast Mechanism: Stimulation of Bone Formation
- Clinical Trials in Osteopenic and Osteoporotic Patients
- Bone-Density Nutrients: Amounts in Studies and Reference Values
- Cautions
- What Is Not Yet Known About Silicon and Bone
- Key Research Papers
- Connections
- Featured Videos
The Bone Matrix Two-Phase Architecture
Bone is a composite material with two distinct phases: a flexible organic matrix (roughly 30% of dry bone weight) and a hard mineral phase (roughly 70%). The organic matrix is mostly type I collagen with smaller contributions from osteocalcin, osteonectin, osteopontin, bone sialoprotein, and proteoglycans. The mineral phase is hydroxyapatite, Ca10(PO4)6(OH)2, deposited as plate-like crystals along the collagen fibrils.
The two phases serve different mechanical functions. The collagen matrix provides tensile strength and flexibility — it is the rope that resists pulling apart. The hydroxyapatite provides compressive strength and rigidity — it is the cement that resists crushing. A bone with normal mineral density but weakened collagen matrix can be just as fracture-prone as a bone with weakened mineralization. This is why BMD measured by DXA does not fully predict fracture risk: it measures the mineral phase but ignores the collagen quality. The clinical mismatch between BMD and fracture in atypical femur fractures associated with long-term bisphosphonate use reflects exactly this disconnect — bisphosphonates preserve mineral density at the cost of collagen turnover quality.
Silicon supports both phases. It is required for the collagen biosynthesis pathway (through prolyl hydroxylase activation, see Connective Tissue) and it appears to participate in hydroxyapatite nucleation at the mineralization front, where new mineral is deposited on the collagen template. The Carlisle electron-microprobe studies of the 1970s first identified silicon enrichment specifically at sites of active osteoid mineralization in developing bone, with silicon concentration dropping as mineralization completed. Silicon thus functions as both a collagen-synthesis cofactor and a mineralization-localization signal — a unique dual role among trace minerals.
The Framingham Offspring Silicon-BMD Study
The Framingham Offspring Cohort is the second-generation arm of the original Framingham Heart Study, started in 1971 to study cardiovascular risk in the children of the original Framingham participants. By the late 1990s, the cohort was middle-aged and had been extensively phenotyped for cardiovascular outcomes; the silicon and BMD analysis was a secondary investigation using existing food-frequency questionnaire data and DXA measurements taken in 1996-2001.
The study was led by Ravin Jugdaohsingh of the Gastrointestinal Laboratory at the Rayne Institute, St Thomas' Hospital, London, with co-authors including Katherine Tucker, Douglas Kiel and Jonathan Powell. The study (published in Journal of Bone and Mineral Research, 2004) included 1,251 men and 1,596 women with usable dietary silicon estimates and hip and lumbar spine DXA. The major findings:
- Men, all ages — significant positive association between dietary silicon intake and hip BMD. Adjusted for age, body mass index (BMI), smoking, alcohol, physical activity, and calcium intake, men in the highest silicon quintile had 9.5% higher hip BMD than men in the lowest quintile.
- Premenopausal women — significant positive association between dietary silicon and hip BMD, with a similar 10% effect size from lowest to highest quintile.
- Postmenopausal women — no significant association at the hip sites — the surprising negative finding that pointed researchers toward an estrogen-silicon interaction.
- Women on hormone replacement therapy (HRT) — the Framingham paper did not report a separate result for women on HRT. The later Aberdeen study (below) did: it found a positive association in women on HRT (r=+0.09), weaker than in late premenopausal women (r=+0.21).
- Effect size context — a 1996 meta-analysis of 11 study populations (Marshall, Johnell and Wedel) found that each 1 standard-deviation drop in BMD raised the risk of fracture about 1.5-fold overall, and about 2.6-fold for hip BMD and hip fracture. If the silicon link were causal, a BMD difference of this size could matter for fracture risk; no silicon study described on this page measured fractures.
An earlier analysis of the original Framingham and Framingham Offspring cohorts (Jugdaohsingh 2002) estimated average silicon intake at 30 and 33 mg/day in men and 24 and 25 mg/day in women, with intake falling with age. The main food sources were beer and bananas in men, and bananas and string beans in women. On average 41% of the silicon eaten in foods was excreted in urine, the study's measure of absorption, and the authors concluded that solid foods are a major source of available silicon.
The study was observational and so cannot prove causation, but the large BMD differences between the highest and lowest of the five intake groups (quintiles), the consistency across both men and premenopausal women, and the biological plausibility of the silicon-collagen mechanism made the Framingham finding the strongest single piece of evidence in the silicon-bone literature. A later observational study in Aberdeen, UK (Macdonald 2012) found a similar link in women with adequate estrogen, and a Korean study in ovariectomized rats (Kim 2009) found that added silicon raised femur and tibia BMD only in calcium-deficient animals.
Estrogen Modulation of the Silicon Effect
The finding that the silicon-BMD association was absent in postmenopausal women prompted a focused follow-up study by Macdonald, Hardcastle, Jugdaohsingh and colleagues using the Aberdeen Prospective Osteoporosis Screening Study. In 3,198 women aged 50-62, average femoral-neck BMD was 2% lower in the quarter of women with the lowest silicon intake (about 16 mg/day) than in the quarter with the highest (about 31.5 mg/day). The link held only in women with adequate estrogen: late premenopausal women (r=+0.21) and women on HRT (r=+0.09), while estrogen-depleted women showed no such association. The interaction between estrogen status and silicon intake stayed significant after adjustment for other factors. Higher silicon intake also went with lower urine markers of bone breakdown and a higher blood marker of bone formation. The authors concluded that estrogen status appears important for how silicon acts in bone, and that further work is needed to explain the mechanism.
The proposed mechanism is that estrogen is required for orthosilicic acid to exert its full osteoblast-stimulating effect. In cell culture, the combination of estradiol plus orthosilicic acid produces synergistic increases in osteoblast collagen synthesis greater than either agent alone. The molecular pathway is not resolved. In the Reffitt 2003 cell study, silicon raised collagen type 1 production without changing the level of collagen type 1 messenger RNA (mRNA), so silicon appears to act after the collagen gene is read, through the collagen-finishing enzyme prolyl hydroxylase, rather than by switching the gene on.
One reading of these results is that silicon alone may do less for bone in postmenopausal women with low estrogen. Sources of estrogen or estrogen-like activity discussed in this context are hormone replacement therapy (including estradiol patches) and phytoestrogen-rich foods such as flaxseed, a source of lignans. The silicon-estrogen interaction is also relevant to interpretation of trial data: trials in osteopenic or osteoporotic women (e.g. Spector 2008) typically include calcium and vitamin D as background and may underestimate the silicon effect if endogenous estrogen is uniformly low across both arms.
Men do not face the equivalent issue because testosterone aromatizes to estradiol throughout adult life, maintaining a baseline estrogenic signal in male bone.
Bioavailability: Beer, Mineral Water, Whole Grains
Dietary silicon comes from three principal sources: cereal grains, beverages (beer, mineral water, coffee), and root and leafy vegetables. The bioavailability differs dramatically by source. Sripanyakorn and colleagues at the Rayne Institute, St Thomas' Hospital, London, measured the urinary recovery of silicon from each source as a proxy for absorption:
- Beer — the highest absorption of any common food. The silicon in beer is largely already in orthosilicic acid form, dissolved during brewing from the silicon-rich barley malt and hops. In nine volunteers, about 55% of the silicon in beer was absorbed, comparable to a pure orthosilicic acid solution. A typical 12 oz beer contains 6 to 12 mg elemental silicon. Across 76 beers tested, the mean was 19.2 mg silicon per liter (median 18.0 mg/L), with no significant difference by country of origin or type of beer.
- High-silicon mineral water — second-highest absorption. Some silica-rich bottled mineral waters, including waters from volcanic sources, contain 30-90 mg silica (silicon dioxide) per liter. Davenward and colleagues (2013) found that drinking up to one liter per day of a silicon-rich mineral water for 12 weeks increased urinary aluminum excretion in people with Alzheimer's disease and in their carers.
- Whole grain cereals — moderate. Oats deliver silicon at 600-800 mg per kg dry weight; barley at 500-700 mg/kg; whole wheat at 200-400 mg/kg. Absorption is roughly 5-10% from the silica-rich aleurone layer (the outer layer of the grain, removed in white-flour milling).
- Root and leafy vegetables — lower silicon content (50-150 mg/kg fresh weight). Absorption is not uniformly low: in the 2009 comparison below, 44% of the silicon in green beans was absorbed, against 4% from bananas.
- Tap water — highly variable depending on geology. Areas with granitic bedrock (Vermont, parts of Scotland) have higher silicon content; areas with limestone bedrock have lower.
A 2009 comparison by the same London group (Sripanyakorn 2009) measured absorption, based on urinary silicon, from eight high-silicon sources: 64% from alcohol-free beer and from monomethyl silanetriol (a supplement form), 44% from green beans, 43% from an orthosilicic acid solution, 17% from choline-stabilized orthosilicic acid (ch-OSA, a supplement form), 4% from bananas and from a magnesium trisilicate antacid, and 1% from colloidal silica. Silicon in its single-molecule (monomeric) form was readily absorbed, while particle forms were absorbed less the more polymerized they were.
The upshot: a diet that includes oatmeal, high-silicon mineral water and some beer delivers substantially more bioavailable silicon than a typical low-grain Western pattern. The Framingham silicon quintile-1 vs quintile-5 contrast (under 14 vs over 40 mg/day) roughly separates diets low in grains and beer from diets rich in whole grains that include beer, and the Framingham authors noted that some of the bone benefit seen with moderate drinking of alcoholic beverages might come from their silicon.
For non-drinkers and people who leave out beer for caloric or health reasons, high-silicon mineral water (1 liter per day) plus daily oatmeal delivers roughly equivalent silicon without alcohol.
The Silicon-Aluminum Interaction
One of silicon's most useful properties is its competitive binding with aluminum in the gastrointestinal tract and renal tubule. Orthosilicic acid forms hydroxyaluminosilicate complexes with Al3+ ions, reducing aluminum absorption across the intestine and increasing urinary aluminum excretion when aluminum is already in circulation. This effect was first demonstrated in the 1970s by Birchall and colleagues at ICI Mond Research, and subsequently developed by Exley and Birchall into a hypothesis-driven research program on silicon as a natural aluminum chelator.
The relevance for bone is that aluminum is itself bone-toxic. Aluminum interferes with hydroxyapatite crystal formation, accumulates in the mineralization front, and produces a distinctive osteomalacia pattern (aluminum bone disease) most clinically familiar from dialysis patients in the 1970s and 80s before phosphate binders were switched away from aluminum hydroxide. Even at sub-clinical exposure levels, aluminum may contribute to age-related bone fragility, particularly in individuals with chronic kidney disease who cannot effectively excrete aluminum.
Silicon's protective effect on bone may therefore have two components: direct osteoblast stimulation and collagen support (the primary effect), plus indirect protection from aluminum-mediated bone matrix interference (a secondary effect). The Davenward 2013 Alzheimer pilot demonstrated that the silicon-aluminum binding works in vivo at the doses obtainable from drinking high-silicon mineral water — an important proof-of-concept for the dietary approach.
Aluminum exposure in modern populations comes primarily from antiperspirants, aluminum cookware in acidic dishes (tomato sauce, coffee), aluminum-containing antacids (such as aluminum-magnesium antacids), aluminum food additives (some baking powders, processed cheese), and tap-water aluminum sulfate flocculants. Less exposure to these sources lowers aluminum intake, and dietary silicon, by the binding described above, may reduce how much of the remainder is absorbed.
The Silicon-Vitamin-D-Vitamin-K2 Axis
No single nutrient builds bone in isolation. The bone-building network includes calcium (the mineral substrate), vitamin D (calcium absorption), vitamin K2 (osteocalcin carboxylation and calcium routing to bone), magnesium (cofactor for vitamin D activation and bone matrix), boron (osteoblast function), and silicon (collagen and mineralization). Nutrition approaches to osteoporosis prevention commonly address all six.
- Vitamin D3 — required for intestinal absorption of dietary calcium and for proper differentiation and function of osteoblasts. The Institute of Medicine (IOM) 2011 report found that practically all people are sufficient at a blood 25-hydroxyvitamin D (25(OH)D) level of at least 20 ng/mL (50 nmol/L), that levels above 30 ng/mL are not consistently associated with increased benefit, and that there may be reason for concern above 50 ng/mL (125 nmol/L).
- Vitamin K2 (menaquinone-7, MK-7) — carboxylates osteocalcin (Glu → Gla), which then binds calcium and directs it into bone matrix rather than into vascular calcifications. K2 also activates matrix Gla protein (MGP), the principal inhibitor of vascular calcification. The K2-D3 combination is particularly important: high vitamin D without K2 may increase vascular calcification risk.
- Calcium — the structural mineral. Best obtained from food (dairy, sardines with bones, leafy greens) rather than high-dose supplements.
- Magnesium — required for activation of vitamin D, for osteoblast function, and as a component of bone matrix. Most adults are below the recommended 320-420 mg/day.
- Silicon — supports collagen matrix and mineralization. Average intakes in the Framingham cohorts were 24-33 mg/day, and the highest Framingham quintile took in over 40 mg/day from food; the ch-OSA trial used 3, 6 or 12 mg/day of silicon.
- Boron — influences calcium and magnesium retention, supports osteoblast differentiation, and modulates sex hormone metabolism. 3-6 mg/day.
The presence of silicon at typical Western dietary levels is a major reason why historical populations with much lower calcium intake than modern Western recommendations (1000-1200 mg/day) nevertheless maintained healthy bone — their grain-and-mineral-water-rich diets delivered abundant silicon and the full bone-building cofactor network.
Osteoblast Mechanism: Stimulation of Bone Formation
The Reffitt 2003 in vitro study established the direct osteoblast-stimulating effect of orthosilicic acid, tested at 0-50 micromolar (blood levels are normally 5-20 micromolar). Human osteoblast-like cells (the MG-63 line, plus two other human osteoblast-like cell types) exposed to orthosilicic acid showed:
- Increased collagen type 1 production — at 10 and 20 micromolar, collagen type 1 synthesis rose 1.75-fold in MG-63 cells, 1.8-fold in a second cell line and 1.45-fold in primary cells, with a smaller rise at 50 micromolar. Collagen type 1 mRNA did not change, and the effect disappeared when the enzyme prolyl hydroxylase was blocked.
- Increased alkaline phosphatase activity — the enzyme that hydrolyzes pyrophosphate to liberate phosphate for hydroxyapatite formation. Alkaline phosphatase (ALP) activity is the standard marker of osteoblast differentiation.
- Increased osteocalcin synthesis — the calcium-binding bone protein produced by mature osteoblasts.
The molecular mechanism is incompletely characterized but appears to act directly on osteoblasts rather than through calcium or phosphate handling. For collagen, the effect worked through prolyl hydroxylase, after the collagen gene is read; the genes for alkaline phosphatase and osteocalcin did show increased expression. The collagen effect was seen in all three cell types tested.
The evidence on bone breakdown (resorption) is mixed. In vitro studies of osteoclast precursors (RAW264.7 line) exposed to orthosilicic acid are described as showing no increase in osteoclast differentiation or bone resorption activity, and some studies suggest mild osteoclast inhibition. In calcium-deficient ovariectomized rats, added silicon raised femur and tibia BMD by reducing bone resorption, with no change in alkaline phosphatase or osteocalcin (Kim 2009). In the Spector 2008 trial, the bone-resorption marker collagen type I C-terminal telopeptide (CTX-I) showed a trend to rise with dose. Whether silicon's net effect in people is mainly bone-building (anabolic, like teriparatide) or mainly a brake on resorption (like bisphosphonates) is therefore not settled.
If silicon's main effect is bone-building, it would complement the more familiar antiresorptive bone agents. The idea that a person on a bisphosphonate could benefit from added silicon, to support the remaining osteoblast bone-formation pathway and the matrix-collagen quality, is a proposal, not a trial result.
Clinical Trials in Osteopenic and Osteoporotic Patients
The Spector 2008 trial (BMC Musculoskeletal Disorders) randomized 184 osteopenic women (spine T-score below -1.5), of whom 136 completed the study, to placebo or ch-OSA at 3, 6 or 12 mg silicon per day, on top of background calcium 1000 mg/day and vitamin D3 800 international units (IU, 20 micrograms)/day for 12 months. All four arms received the same calcium and vitamin D background.
The findings:
- Serum procollagen type I N-terminal propeptide (PINP) — a biomarker of new collagen synthesis — was the only marker significantly different from placebo at 12 months, for the 6 and 12 mg/day doses, without a clear dose-response effect. Other bone-formation markers showed only a trend.
- CTX-I — the marker of bone breakdown — showed a trend for a dose-corresponding increase.
- Femoral neck BMD — significant for the 6 mg dose only in a post-hoc subgroup analysis of women whose baseline femur T-score was below -1.
- Lumbar spine BMD — did not change significantly.
- Safety — no ch-OSA-related adverse events were observed, and blood safety tests stayed within the normal range.
The trial was relatively short (12 months) and the bone-density changes were modest. However, the PINP biomarker increase was the predicted effect of an osteoblast-stimulating, collagen-supporting agent, and the femoral-neck signal, from a post-hoc subgroup only, was consistent with that mechanism. Longer, larger trials would be needed to fully establish silicon as an osteoporosis treatment; the trial's authors concluded that ch-OSA with calcium and vitamin D3 had a potential beneficial effect on bone collagen compared with calcium and vitamin D3 alone.
Eisinger and Clairet (1993) reported a retrospective study of 53 osteoporotic women followed for 14-22 months. The 8 women treated with silicon had a significant increase in femoral BMD, while etidronate (13 women) produced a slight, statistically non-significant increase in vertebral BMD.
Bone-Density Nutrients: Amounts in Studies and Reference Values
The amounts below are those used in the studies on this page, set in official reference values, or commonly described for bone health. They are reported as information.
- Dietary silicon — average intakes in the Framingham cohorts were 24-33 mg/day, and the highest Framingham quintile took in over 40 mg/day. Food amounts: daily oatmeal (~6-10 mg), high-silicon mineral water (1 L delivers 15-50 mg depending on the water), and 1-2 servings of barley or whole-grain rye bread (~8-12 mg per serving).
- Beer (in moderation) — a well-absorbed source (about 55% of its silicon absorbed). Chronic heavy drinking is a major risk factor for osteoporosis (see Cautions), and beer is not an option for people who stay away from alcohol for medical, religious, or addiction-recovery reasons.
- ch-OSA supplement (optional) — the Spector 2008 trial used 3, 6 or 12 mg/day of silicon as ch-OSA. Supplements are used by people whose diet includes few grains and little mineral water, and by adults with known osteopenia/osteoporosis alongside other bone nutrients.
- Vitamin D3 — the IOM's 2011 Recommended Dietary Allowance is 600 international units/day for adults up to age 70 and 800 international units/day above 70, with a Tolerable Upper Intake Level of 4,000 international units/day. The IOM found practically everyone sufficient at a 25(OH)D level of 20 ng/mL and raised concern above 50 ng/mL.
- Vitamin K2 (menaquinone-7) — intakes of 90-180 mcg/day are used in this context, with the aim of directing calcium into bone rather than arteries.
- Magnesium — 320-420 mg/day total intake (food + supplement) is the adult recommended range cited above. Glycinate and malate forms are described as well tolerated.
- Boron — intakes of 3-6 mg/day are described, obtainable from prunes (3-4 prunes per day deliver 1-2 mg) or supplemental sodium borate.
- Weight-bearing exercise — 3-5 sessions per week is a common pattern. The mechanical-loading signal is the dominant non-nutritional driver of bone formation.
- Lower aluminum exposure — aluminum-containing antacids, antiperspirants, and cookware are the everyday sources described above.
- Monitoring — DXA scans are commonly repeated at 12-24 months when osteopenia/osteoporosis is established; for prevention in younger adults, 5-year intervals are typical.
Cautions
- Advanced chronic kidney disease — silicon is renally excreted, and clearance is impaired in chronic kidney disease (CKD) stage 4 and 5, so supplemental silicon can build up in people with advanced kidney disease.
- Aluminum exposure history — in people with high historical aluminum exposure (chronic aluminum-antacid use, occupational aluminum exposure), low bone density can come from aluminum bone disease. Aluminum-related osteomalacia is treated with aluminum chelation, not with silicon repletion alone.
- Beer caveats — chronic high alcohol intake is a major risk factor for osteoporosis (alcohol suppresses osteoblast activity and impairs vitamin D metabolism). The silicon benefit of moderate beer consumption is not preserved at heavy intake (more than 3 drinks per day for men, 2 for women). Heavy beer drinkers gain neither silicon benefit nor bone benefit and incur substantial alcohol harm.
- Vitamin K interactions with anticoagulants — added vitamin K2 counteracts warfarin and other vitamin K antagonist anticoagulants and shifts the international normalized ratio (INR) blood-clotting test. Direct oral anticoagulants (DOACs) such as apixaban and rivaroxaban do not work through vitamin K and are not affected.
- Calcium upper limits — the IOM's 2011 Tolerable Upper Intake Level for total calcium (food + supplement) is 2,500 mg/day for adults aged 19-50 and 2,000 mg/day from age 51; 1,200 mg/day is the Recommended Dietary Allowance for women over 50 and everyone over 70, not an upper limit. High calcium intake has been associated with vascular calcification risk. Silicon does not raise calcium needs.
- Pregnancy — ch-OSA has not been studied in pregnancy. Dietary silicon from food sources is presumed safe; the safety of supplemental ch-OSA in pregnancy is unknown.
This content is provided for informational purposes only and does not constitute medical advice. The cautions above matter most for people with osteoporosis or chronic kidney disease, and for people taking osteoporosis medicines or warfarin.
What Is Not Yet Known About Silicon and Bone
A 2024 umbrella review of controlled animal studies (Pritchard and Nielsen) found that the silicon amounts tested ranged from 0.003 to 863 mg per kg of body weight per day. Silicon consistently helped bone and mineral metabolism only at around 139 mg per kg of body weight per day, a level the authors called likely unfeasible to attain in humans; for comparison, the review cites a current human intake recommendation of 25 mg per day in total. Missing data in the published animal studies made an effective threshold hard to pin down, and the authors asked for future studies to test it directly.
In people, the evidence described on this page is observational (the Framingham and Aberdeen studies), one small retrospective study (Eisinger 1993), and one 12-month trial that measured bone markers and BMD rather than fractures (Spector 2008).
Key Research Papers
- Jugdaohsingh R, Tucker KL, Qiao N et al. (2004). Dietary silicon intake is positively associated with bone mineral density in men and premenopausal women of the Framingham Offspring cohort. Journal of Bone and Mineral Research. — PubMed PMID: 14969400
- Macdonald HM, Hardcastle AC, Jugdaohsingh R, Fraser WD, Reid DM, Powell JJ (2012). Dietary silicon interacts with oestrogen to influence bone health: evidence from the Aberdeen Prospective Osteoporosis Screening Study. Bone. — PubMed PMID: 22173054
- Spector TD, Calomme MR, Anderson SH et al. (2008). Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females. BMC Musculoskeletal Disorders. — PubMed PMID: 18547426
- Reffitt DM, Ogston N, Jugdaohsingh R et al. (2003). Orthosilicic acid stimulates collagen type 1 synthesis and osteoblastic differentiation in human osteoblast-like cells in vitro. Bone. — PubMed PMID: 12633784
- Carlisle EM (1970). Silicon: a possible factor in bone calcification. Science. — PubMed PMID: 5410261
- Carlisle EM (1981). Silicon: a requirement in bone formation independent of vitamin D1. Calcified Tissue International. — PubMed PMID: 6257332
- Sripanyakorn S, Jugdaohsingh R, Elliott H et al. (2004). The silicon content of beer and its bioavailability in healthy volunteers. British Journal of Nutrition. — PubMed PMID: 15005826
- Davenward S, Bentham P, Wright J et al. (2013). Silicon-rich mineral water as a non-invasive test of the 'aluminum hypothesis' in Alzheimer's disease. Journal of Alzheimer's Disease. — PubMed PMID: 22976072
- Eisinger J, Clairet D (1993). Effects of silicon, fluoride, etidronate and magnesium on bone mineral density: a retrospective study. Magnesium Research. — PubMed PMID: 8292498
- Price CT, Koval KJ, Langford JR (2013). Silicon: a review of its potential role in the prevention and treatment of postmenopausal osteoporosis. International Journal of Endocrinology. — PubMed PMID: 23762049
- Jugdaohsingh R (2007). Silicon and bone health. Journal of Nutrition, Health & Aging. — PubMed PMID: 17435952
- Powell JJ, McNaughton SA, Jugdaohsingh R et al. (2005). A provisional database for the silicon content of foods in the United Kingdom. British Journal of Nutrition. — PubMed PMID: 16277785
- Kim MH, Bae YJ, Choi MK, Chung YS (2009). Silicon supplementation improves the bone mineral density of calcium-deficient ovariectomized rats by reducing bone resorption. Biological Trace Element Research. — PubMed PMID: 19034393
- Sripanyakorn S, Jugdaohsingh R, Dissayabutr W et al. (2009). The comparative absorption of silicon from different foods and food supplements. British Journal of Nutrition. — PubMed PMID: 19356271
- Jugdaohsingh R, Anderson SH, Tucker KL et al. (2002). Dietary silicon intake and absorption. American Journal of Clinical Nutrition. — PubMed PMID: 11976163
- Pritchard A, Nielsen BD (2024). Silicon Supplementation for Bone Health: An Umbrella Review Attempting to Translate from Animals to Humans. Nutrients. — PubMed PMID: 38337624
- Marshall D, Johnell O, Wedel H (1996). Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. — PubMed PMID: 8634613
- Institute of Medicine (2011). Dietary Reference Intakes for Calcium and Vitamin D. Summary. Washington, DC: The National Academies Press. — doi:10.17226/13050
PubMed Topic Searches
Connections
- All Minerals
- Silicon Overview
- Silicon Benefits Hub
- Silicon for Connective Tissue
- Silicon for Hair and Nails
- Silicon for Cardiovascular Health
- Calcium
- Magnesium
- Boron
- Manganese and Bone Formation
- Vitamin D3
- Vitamin K2 (Menaquinone-7)
- Vitamin C
- Osteoporosis
- Aluminum (Bone Toxin)
- Oats (Dietary Silicon)
- Barley
- Collagen
- Proline
- Deficiency
- Toxicity
- History